Stay updated on Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe ClinicalTrials.gov record for the pembrolizumab prostate cancer study is accessible, displaying its study overview, eligibility criteria, treatment plan, outcomes, and record details.SummaryDifference57%

- Check17 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner announces an NIH website transition and says agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check31 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now shows a 403 Forbidden error, indicating access to the study record is blocked. The previous content and navigation for the record is replaced by an error page.SummaryDifference20%

Stay in the know with updates to Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.